Ptc Therapeutics (PTCT) Non-Current Deffered Revenue (2012 - 2020)

Ptc Therapeutics' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2020.

• In Q1 2020, Non-Current Deffered Revenue fell 80.03% year-over-year to $1.8 million; the TTM figure through Mar 2020 stood at $1.8 million (down 80.03% YoY), while the FY2019 annual figure was $3.4 million, down 64.87% from the prior year.
• Non-Current Deffered Revenue for Q1 2020 stood at $1.8 million, down from $3.4 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $11.2 million in Q3 2018, with the low at $1.6 million in Q4 2016.
• The 5-year median for Non-Current Deffered Revenue is $7.2 million (2017), against an average of $6.4 million.
• The sharpest annual moves came in 2017 and 2020: Non-Current Deffered Revenue surged 401.2% in 2017, then slumped 80.03% in 2020.
• Ptc Therapeutics' Non-Current Deffered Revenue stood at $1.6 million in 2016, then soared by 401.2% to $8.0 million in 2017, then increased by 22.23% to $9.7 million in 2018, then plunged by 64.87% to $3.4 million in 2019, then plunged by 48.23% to $1.8 million in 2020.
• Business Quant data shows PTCT's Non-Current Deffered Revenue at $1.8 million in Q1 2020, $3.4 million in Q4 2019, and $5.5 million in Q3 2019.